Skip to Content

Promising Result for Patients with Prurigo Nodularis: Targeting IL-4 and IL-13 Signaling

Directly from EADV 2023, Martin Metz from Charité’s Institute of Allergology in Berlin, Germany, discusses the significance of dual inhibition of IL-13 and IL-4 in prurigo nodularis.

Martin Metz

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top